Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

54.30 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?
Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide. 
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Top Pick for Affordable Growth Investors
NOVO-NORDISK A/S (NVO) offers affordable growth with strong revenue, earnings growth, and fair valuation, making it a top pick for balanced investors. 
Via Chartmill
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
Via Stocktwits
Earnings Scheduled For August 6, 2025
 
Via Benzinga
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Fir
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates. 
Via Benzinga
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.
An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise. 
Via Investor's Business Daily
Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk
Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 earnings beat and raised guidance. 
Via Benzinga
Topics Earnings
Why Novo Nordisk Stock Slipped Today
The Danish pharmaceutical company is fighting a competitive war on several fronts. 
Via The Motley Fool
Topics Lawsuit
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful
Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021. 
Via Stocktwits
Topics Earnings
Law Offices of Howard G. Smith Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
Law Offices of Frank R. Cruz Encourages Novo Nordisk A/S (NVO) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
LifeMD Stock Plummets 40%. Why Weight Loss Isn't Just A Gimme.
The company is struggling with several headwinds as it works to develop its obesity plan. 
Via Investor's Business Daily
Why Is Everyone Talking About Novo Nordisk Stock?
Competition is hurting sales of critical products. 
Via The Motley Fool
Novo Nordisk Slumps As It Cautions 'Unsafe And Unlawful' Knockoffs Will Pressure Wegovy
The company says it's working to ensure patients only receive semaglutide produced by Novo Nordisk. 
Via Investor's Business Daily
Topics Earnings
Shareholders of Novo Nordisk A/S Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders of Novo Nordisk A/S Should Contact Levi &amp; Korsinsky Before September 30, 2025 to Discuss Your Rights - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
A Rough Day for "Dividend Knights"
Between battered industries and overlooked opportunities, plenty of dividend-paying companies have slipped. 
Via The Motley Fool
Compounded GLP-1s And Competition Force Novo Nordisk To Slash Outlook
Novo Nordisk reported Q2 sales of $11.7 billion, missing consensus. Sales increased by 13% in Danish kroner, driven by GLP-1 diabetes and obesity care sales. 
Via Benzinga
Bryan Johnson Spent Millions To Be 18 Again—Says Novo Nordisk's Ozempic Anti-Aging Hype Is Misleading: 'Data Is Not There'
Tech entrepreneur Bryan Johnson refutes claims that Novo Nordisk AS's Ozempic demonstrates anti-aging properties. 
Via Benzinga
Novo Nordisk Edges Up Premarket As Q2 Wegovy Sales Defy Copycat Threats: Retail Stays Bullish Amid Tariff Pressure
The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance. 
Via Stocktwits
Topics Government World Trade
Investor Alert: Robbins LLP Informs Investors of the Novo Nordisk A/S Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
US Market Under Pressure: Amazon, Eastman Chemical, and Hims & Hers Among Top Losers
The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
92 93 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.